Incyte Corporation has 7 Schedule 13D or 13G filings on record since 2025-10-17. 5 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Baker Bros. Advisors LP | 15.6% | 30,865,077 | SCHEDULE 13D/A, 2026-05-11 | 2026-05-07 |
| BlackRock, Inc. | 7.8% | 15,242,171 | SCHEDULE 13G/A, 2025-10-17 | 2025-09-30 |
| Vanguard Capital Management | 6.32% | 12,591,630 | SCHEDULE 13G, 2026-04-30 | 2026-03-31 |
| Dodge & Cox | 6.2% | 12,252,356 | SCHEDULE 13G/A, 2026-05-14 | 2026-03-31 |
| State Street Corporation | 5% | 9,677,414 | SCHEDULE 13G, 2025-11-10 | 2025-09-30 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-27 | 2026-03-13 |
Purpose of Transaction (Item 4)
Baker Bros. Advisors LP
Item 4 of Schedule 13D is supplemented and superseded, as the case may be, as follows: On May 8, 2026 the Adviser acquired beneficial ownership of 15,000 shares of common stock ("Common Stock") of Incyte Corporation (the "Issuer"), as a result of the exercise of 15,000 options to purchase Common Stock at $84.53 per share (the "Exercised Stock Options") held directly by Julian C. Baker. Julian C. Baker currently serves on the Issuer's board of directors (the "Board") as a representative of the Funds. The policy of the Funds and the Adviser does not permit managing members of the Adviser GP or full-time employees of the Adviser to receive compensation for serving as directors of the Issuer, and the Funds are instead entitled to the pecuniary interest in the Exercised Stock Options. Julian C. Baker, as an agent in his capacity as a director of the Issuer, entered into a proceeds agreement (the "Proceeds Agreement") with the Adviser on May 7, 2026. Pursuant to the Proceeds Agreement, Julian C. Baker agreed that, with respect to the Exercised Stock Options and the Common Stock received as a result of the exercise of the Exercised Stock Options on May 8, 2026, the Adviser will have dispositive power as well as the ability to control the timing of exercise of the Exercised Stock Options and that any proceeds from the sale of the Common Stock will be remitted to the Adviser net of brokerage commissions. Other than through their control of the Adviser, Felix J. Baker and Julian C. …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-05-11; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-10-17 | BlackRock, Inc. | 7.8% | SCHEDULE 13G/A |
| 2025-11-10 | State Street Corporation | 5% | SCHEDULE 13G |
| 2026-02-10 | Baker Bros. Advisors LP | 15.7% | SCHEDULE 13D/A |
| 2026-03-27 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-04-30 | Vanguard Capital Management | 6.32% | SCHEDULE 13G |
| 2026-05-11 | Baker Bros. Advisors LP | 15.6% | SCHEDULE 13D/A |
| 2026-05-14 | Dodge & Cox | 6.2% | SCHEDULE 13G/A |
Tools for this story
Each opens in a new tab, filled in for Incyte Corporation. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.